

Locate Georgia cancer trials: www.georgiacancertrials.org
Find Georgia oncologists: www.georgiacore.org/directory

Early Stage Breast Cancer Study in Interim Analysis (EU 822-03)

Ruth M. O'Regan, MD, Principal Investigator and Amelia Zelnak, Medical Director, have announced that their randomized phase II trial of preoperative docetaxel and capecitabine given sequentially or concurrently for Her2 negative breast cancers is in interim analysis and temporarily closed to accrual. The study is sponsored by Georgia CORE and funded by Sanofi-Aventis.

51 patients (64% of a projected 80 patients) from 7 sites in the CORE Research Network have enrolled in the study. Participating sites include: Amos Cancer Center/Columbus Regional, Augusta Oncology Associates, Central Georgia Cancer Care, Dekalb Medical/Georgia Cancer Specialists, Emory Winship Cancer Institute, Georgia Cancer Center for Excellence/Grady Health System, Wellstar Health System/Northeast Georgia Oncology Centers.

Preliminary results of the study were reported at San Antonio Breast Cancer Symposium in December of 2008. The report was the first of its kind co-authored by academic and community oncologists and clinical research professionals active in the Georgia CORE network including Drs. Gabram, Hermann, O'Regan, Schnell, Srinivasiah and Zelnak. 49% of the patients enrolled in the study at the time of the report were African American.

Her2 Over Expressing Early Stage Breast Cancer Study Actively Accruing

ABX018, the neoadjuvant trial of Trastuzumab in combination with dose-dense ABI007 (Abraxane) followed by Vinorelbine sponsored by Georgia CORE and funded by Abraxis, is actively accruing patients.


Currently 14 (28% of a projected 50 patients) have been enrolled from the following CORE Research Network sites: Dekalb Medical/Georgia Cancer Specialists, Emory/Winship Cancer Institute, Georgia Cancer Center for Excellence/Grady Health System, Northeast Georgia Cancer Care, Piedmont Hospital/Peachtree Hematology Oncology Consultants.

Georgia CORE GOG Consortium Membership Performance

Georgia CORE's Consortium has received provisional membership status from the Gynecologic Oncology Group. According to Donald G. Gallup, MD, Principal Investigator, this unique statewide Consortium offers Georgia investigators the opportunity to open GOG trials provided that the Consortium accrues at least 150 membership points in specific categories during the year.

Currently active members of the Georgia CORE GOG Consortium, Mercer/Memorial University and the Medical College of Georgia, are on target to accrue half of the points by mid-year, ensuring that provisional membership status is maintained. The sites are accruing a greater percentage of patients to high priority GOG studies. Mitchell Z. Berger, MD has recently announced plans to open GOG studies at the Georgia Cancer Center for Excellence at Grady Health System.

Figure 1



For study information contact:

Diane Hicklin-Coleman, MPA
Research Director
770-313-4055
404-588-4082
dhicklin@georgiacore.org

Event Calendar:

4/15/09- Breast Cancer Working Group Meeting 6:30pm

Sponsored by Monogram Biosciences

Featured Presentation
Measuring the Target – A Functional Proteomic Approach to Personalized Medicine”

Panel Discussion
Her2 Testing and Management of Small Her2+ Cancers

RSVP to Shaunta Wright at swright@georgiacore.org or 404-584-8697

Georgia CORE™
50 Hurt Plaza
Suite 704
Atlanta, GA 30303
404-523-8735

www.georgiacore.org
info@georgiacore.org

Georgia CORE is generously supported by the Georgia Cancer Coalition, Emory Winship Cancer Institute and Georgia oncologists dedicated to today's cancer care and tomorrow's cancer cure.